By Stephen L Kanaval via Iris.xyz

Over the last six months in the cannabis industry, topicals have emerged as a mass market method to ease CBD and other cannabinoids to consumers. CVS Pharmacy CVS [NYE] – $56.04 recently announced it would be selling CBD products in eight states as an alternative source of pain relief.

“We are carrying hemp-derived CBD products in select states to help meet consumer demand for alternative care options,” said CVS Health Spokesperson, Mike DeAngelis.

And, while CBD or cannabidiol has become a common name to consumers – with female celebrities even rubbing it on their feet to walk in heels at the Academy Awards – it is just one compound within the hemp plant. Cannabigerol (CBG) is by most accounts considered a minor cannabinoid as it is not present in all strains, but early testing on this non-psychoactive chemical precursor to both CBD and THC have shown positive results for a wide variety of maladies including Huntington’s Disease and glaucoma.

So, it caught our attention when Axim Biotechnologies, Inc. AXIM [OTCQB] – $1.55  announced the receipt of a patent for topical cream containing a blend of both CBD and CBG.

Axim’s topical cream and a growing portfolio related to chewing gum

This particular cream will be formulated for patients with atopic dermatitis, and, according to the company, is supposed to be one of the first CBG products available to consumers.

Click here to read more on Iris.

Subscribe to our free daily newsletters!
Please enter your email address to subscribe to ETF Trends' newsletters featuring latest news and educational events.